Drugs / Rutin
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06916494 | May 2025 → Jan 2026 overdue | urinary bladder cancer | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07310407 | Jan 2026 → Jan 2027 expected | metabolic dysfunction-associated steatotic liver disease | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06579482 | Nov 2024 → May 2025 | chronic venous insufficiency | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase 4 | NCT06705777 | Sep 2024 → Sep 2025 | hemorrhoid | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06718452 | Apr → Oct 2026 expected | tinnitus | University of Campania Luigi Vanvitelli | Not yet recruiting | No outcome recorded |
| — | NCT01254006 | — | glaucoma | University of Roma La Sapienza | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT07370220 Comparator | Feb → May 2025 | ulcerative colitis | Benha University | Completed | No outcome recorded |
| Phase 3 | NCT04955145 Comparator | Jun 2021 → Jan 2022 | end stage renal failure | Ain Shams University | Unknown | No outcome recorded |
| — | NCT07147842 Comparator | Nov 2024 → Jan 2025 | ulcerative colitis | Benha University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rutin | “Aesculus Hippocastanum 50mg, Polygonum Acre 10mg, Smilax Pepyracea 40mg, Rutin 20mg Versus Diosmin 450mg and Hesperidin 50mg Tablets in Chronic Venous Insufficiency After 3...” NCT06579482 ↗8“Aesculus Hippocastanum 10 mg, Polygonum Acre 10 mg, Smilax Papyracea 40 mg, Rutin 20 mg Tablets” NCT06705777 ↗ “Ascorbic Acid/Rutoside 60 tablet , each tablet contains: Rutin 60mg and Ascorbic acid 160mg” NCT04955145 ↗ |
| Action | Inhibit | “Rutin Therapy Reduces Ulcerative Colitis Disease Activity By Inhibiting The NOD-Like Receptor Protein 3 (NLRP3) Inflammasome” NCT07147842 ↗ |
| Route | Oral | “Oral administration of two tablets containing 60 mg Rutin + 160 mg Vitamin C, taken three times daily for 12 weeks.” NCT07310407 ↗ |
| Target | NLRP3 | “Rutin Therapy Reduces Ulcerative Colitis Disease Activity By Inhibiting The NOD-Like Receptor Protein 3 (NLRP3) Inflammasome” NCT07147842 ↗ |